Novel type of cell death in Huntington's disease may lead to effective new therapies

Researchers centered at Tokyo Medical and Dental University identify novel type of cell death in Huntington's disease that may uncover new treatments.

In Huntington's disease (HD), the huntingtin gene is mutated, causing progressive neuronal death. This leads to defects in movement, behavior, and cognitive ability. Apoptosis, autophagy, and necrosis are the three main types of cell death, but researchers have not yet been able to determine what type of cell death causes neurodegeneration in the brain of HD patients.

See Also: Study identifies new biomarkers for Huntington's disease

In a new study, researchers examined the nature of cell death in HD using newly developed imaging techniques. The effects of mutant huntingtin in neuronal cells were visualized by live cell imaging. With this approach, the authors identified a novel type of cell death associated with mutant huntingtin, which they called ballooning cell death (BCD). These cells gradually expanded like a balloon, until they ruptured.

To characterize the specific nature of BCD, the authors examined different cellular organelles by live cell imaging. "The endoplasmic reticulum was the main origin of ballooning," study first author Ying Mao explains. "Rupture of the endoplasmic reticulum into the cytosol was followed by gradual cell body ballooning, nuclear shrinkage, and cell rupture."

The authors observed the same phenomena in vivo using two-photon endoplasmic reticulum imaging in a HD mouse model.

Pharmacological inhibitors and genetic interventions showed that BCD was not like apoptosis or autophagy. "We noticed multiple similarities between BCD and a unique form of necrosis called TRIAD, which is caused by inhibition of RNA polymerase II in neurons," corresponding author Hitoshi Okazawa explains. "Based on our existing knowledge of how TRIAD is regulated, we were able to show that BCD is mediated by impaired TEAD/YAP transcription."

Read Next: New evidence: How amino acid cysteine combats Huntington's disease

These revelations provided the opportunity to test potential therapeutic targets for HD. The researchers introduced S1P and up-regulated TEAD/YAP transcription in HD mice. This stabilized endoplasmic reticulum and completely stopped the decline of motor function, suggesting that targeting TEAD/YAP-dependent necrosis may lead to development of effective therapies for HD.

Note: Material may have been edited for length and content. For further information, please contact the cited source.

Tokyo Medical and Dental University   press release

Publication

Mao Y et al. Targeting TEAD/YAP-transcription-dependent necrosis, TRIAD, ameliorates Huntington’s disease pathology.   Human Molecular Genetics, Published September 6 2016. doi: 10.1093/hmg/ddw303